SEGMENT INFORMATION - Profitability (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2025	Oct. 31, 2024	Oct. 31, 2023
Select income statement components
Net revenue	$ 6,948	$ 6,510	$ 6,833
Cost of revenue	3,305	2,975	3,368
Research and Development Expense	455	479	481
Selling, general and administrative	1,709	1,568	1,634
Income from operations	1,479	1,488	1,350
Share-based compensation expense	129	130	112
Depreciation expense	178	149	128
Operating Segments
Select income statement components
Income from operations	1,783	1,721	1,875
Life Sciences and Diagnostics Markets
Select income statement components
Net revenue	2,726	2,466	2,780
Life Sciences and Diagnostics Markets | Operating Segments
Select income statement components
Net revenue	2,726	2,466	2,780
Cost of revenue	1,301	1,121	1,205
Research and Development Expense	248	250	269
Selling, general and administrative	641	611	633
Income from operations	536	484	673
Share-based compensation expense	41	46	48
Depreciation expense	97	72	60
Agilent CrossLab
Select income statement components
Net revenue	2,908	2,747	2,656
Agilent CrossLab | Operating Segments
Select income statement components
Net revenue	2,908	2,747	2,656
Cost of revenue	1,297	1,185	1,188
Research and Development Expense	106	105	103
Selling, general and administrative	559	532	526
Income from operations	946	925	839
Share-based compensation expense	46	48	40
Depreciation expense	56	54	46
Applied Markets
Select income statement components
Net revenue	1,314	1,297	1,397
Applied Markets | Operating Segments
Select income statement components
Net revenue	1,314	1,297	1,397
Cost of revenue	599	580	615
Research and Development Expense	93	94	100
Selling, general and administrative	321	311	319
Income from operations	301	312	363
Share-based compensation expense	21	24	24
Depreciation expense	$ 25	$ 23	$ 22